Published in Pharmacoepidemiol Drug Saf on July 05, 2012
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf (2014) 1.18
Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes. Oncotarget (2017) 0.87
Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study. Pharmacotherapy (2013) 0.76
Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. BMC Pharmacol Toxicol (2015) 0.75
The quality of Medicaid and Medicare data obtained from CMS and its contractors: implications for pharmacoepidemiology. BMC Health Serv Res (2017) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Role of computerized physician order entry systems in facilitating medication errors. JAMA (2005) 26.32
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Gestational hypertension and preeclampsia in living kidney donors. N Engl J Med (2014) 7.25
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf (2007) 5.93
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med (2003) 5.09
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Oral contraceptives and the risk of breast cancer. N Engl J Med (2002) 4.85
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol (2003) 4.27
Design of a national distributed health data network. Ann Intern Med (2009) 4.09
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Handling drop-out in longitudinal studies. Stat Med (2004) 3.87
Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation (2010) 3.78
Classification and regression tree analysis in public health: methodological review and comparison with logistic regression. Ann Behav Med (2003) 3.74
Clinical and organizational factors associated with feeding tube use among nursing home residents with advanced cognitive impairment. JAMA (2003) 3.66
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology (2004) 3.57
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41
Unintended effects of a computerized physician order entry nearly hard-stop alert to prevent a drug interaction: a randomized controlled trial. Arch Intern Med (2010) 3.31
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol (2006) 3.30
Weight gain in the first week of life and overweight in adulthood: a cohort study of European American subjects fed infant formula. Circulation (2005) 3.28
The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf (2005) 3.24
Deceased organ donation consent rates among racial and ethnic minorities and older potential donors. Crit Care Med (2013) 3.22
Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ (2013) 3.22
Statin use and the risk of 10 cancers. Epidemiology (2007) 3.17
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med (2012) 3.08
One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med (2014) 3.07
Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res (2006) 3.06
Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage (2003) 3.05
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93
Clinical risk factors for primary graft failure following lung transplantation. Chest (2003) 2.92
Inter-rater reliability of nursing home quality indicators in the U.S. BMC Health Serv Res (2003) 2.83
The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med (2006) 2.74
The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf (2012) 2.70
Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int (2010) 2.59
Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA (2002) 2.58
Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS (2006) 2.57
The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med (2005) 2.57
Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl (2005) 2.53
Retrospective drug utilization review, prescribing errors, and clinical outcomes. JAMA (2003) 2.51
Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ (2002) 2.46
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43
Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol (2002) 2.39
Evidence of dysregulation of dendritic cells in primary HIV infection. Blood (2010) 2.39
Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol (2011) 2.36
Vitamin and mineral use and risk of prostate cancer: the case-control surveillance study. Cancer Causes Control (2008) 2.35
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med (2005) 2.34
Effects of childhood primary hypertension on carotid intima media thickness: a matched controlled study. Hypertension (2006) 2.33
The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol (2007) 2.32
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Where people die: a multilevel approach to understanding influences on site of death in America. Med Care Res Rev (2007) 2.23
A test of financial incentives to improve warfarin adherence. BMC Health Serv Res (2008) 2.23
The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol (2002) 2.21
Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation (2012) 2.19
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 2.17
Managed problem solving for antiretroviral therapy adherence: a randomized trial. JAMA Intern Med (2013) 2.16
Statin use and the risk of breast and prostate cancer. Epidemiology (2002) 2.15
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 2.15
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf (2002) 2.12
White paper on CTSA consortium role in facilitating comparative effectiveness research: September 23, 2009 CTSA consortium strategic goal committee on comparative effectiveness research. Clin Transl Sci (2010) 2.09
Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. J Am Coll Cardiol (2011) 2.09
Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation (2003) 2.07
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation (2009) 2.06
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics (2012) 2.04
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis (2008) 2.03
Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med (2009) 2.02
Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail (2011) 2.01
Type I and II endometrial cancers: have they different risk factors? J Clin Oncol (2013) 2.01
Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiol Drug Saf (2013) 2.01
Prediction modeling using EHR data: challenges, strategies, and a comparison of machine learning approaches. Med Care (2010) 2.01
Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med (2008) 1.99
Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer (2006) 1.98
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95
Impact of primary graft failure on outcomes following lung transplantation. Chest (2005) 1.92
Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest (2003) 1.90
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl (2005) 1.87